2021-13593. Watson Laboratories, Inc. et al.; Withdrawal of Approval of 36 Abbreviated New Drug Applications  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA or Agency) is withdrawing approval of 36 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

    DATES:

    Approval is withdrawn as of July 26, 2021.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, Martha.Nguyen@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

    Application No.DrugApplicant
    ANDA 062142Doxycycline Hyclate Capsules, Equivalent to (EQ) 50 milligrams (mg) base and EQ 200 mg baseWatson Laboratories, Inc. (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.), 400 Interpace Pkwy., Building A, Parsippany, NJ 07054.
    ANDA 062497Doxycycline Hyclate Capsules, EQ 50 mg base and EQ 100 mg baseTeva Pharmaceuticals USA, Inc. 400 Interpace Pkwy., Building A, Parsippany, NJ 07054.
    ANDA 065152Cephalexin Capsules, EQ 250 mg base and EQ 500 mg baseYung Shin Pharmaceutical Ind. Co. Ltd., authorized U.S. agent, Carlsbad Technology, Inc./Simon Law, 5922 Farnsworth Ct., Suite 101, Carlsbad, CA 92008.
    ANDA 070550Propranolol Hydrochloride (HCl) Tablets, 40 mgWatson Laboratories, Inc.
    ANDA 070551Propranolol HCl Tablets, 80 mgDo.
    ANDA 070943Oxazepam Capsules, 10 mgIVAX Pharmaceuticals Inc. (an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.), 400 Interpace Pkwy., Building A, Parsippany, NJ 07054.
    ANDA 070945Oxazepam Capsules, 30 mgDo.
    ANDA 071446Temazepam Capsules, 15 mgWatson Laboratories, Inc.
    ANDA 071447Temazepam Capsules, 30 mgDo.
    ANDA 072952Oxazepam Capsules, 10 mgDo.
    ANDA 073092Baclofen Tablets, 10 mgDo.
    Start Printed Page 33719
    ANDA 074400Diflunisal Tablets, 250 mg and 500 mgDo.
    ANDA 074432Diclofenac Sodium Delayed Release Tablets, 50 mg and 75 mgPliva, Inc. (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.), 400 Interpace Pkwy., Building A, Parsippany, NJ 07054.
    ANDA 074460Piroxicam Capsules, 10 mg and 20 mgWatson Laboratories, Inc.
    ANDA 074585Indapamide Tablets, 1.25 mg and 2.5 mgDo.
    ANDA 074698Baclofen Tablets, 10 mg and 20 mgDo.
    ANDA 074711Mexiletine HCl Capsules, 150 mg, 200 mg and 250 mgDo.
    ANDA 074723Diclofenac Sodium Delayed Release Tablets, 50 mgTeva Pharmaceuticals USA, Inc.
    ANDA 074852Diltiazem HCl Extended Release Capsules, 120 mg, 180 mg, and 240 mgActavis Laboratories FL, Inc. (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.), 400 Interpace Pkwy., Building A, Parsippany, NJ 07054.
    ANDA 074865Mexiletine HCl Capsules, 150 mg, 200 mg, and 250 mgWatson Laboratories, Inc.
    ANDA 074870Acyclovir Tablets, 400 mg and 800 mgActavis Elizabeth LLC (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.), 400 Interpace Pkwy., Building A, Parsippany, NJ 07054.
    ANDA 075101Acyclovir Capsules, 200 mgWatson Laboratories, Inc.
    ANDA 076022Fluoxetine HCl Capsules, EQ 10 mg base and EQ 20 mg baseCarlsbad Technology, Inc., 5922 Farnsworth Ct., Carlsbad, CA 92008.
    ANDA 078345Prednisolone Sodium Phosphate Solution, EQ 15 mg base/5 milliliters (mL)Amneal Pharmaceuticals, 85 Adams Ave., Hauppauge, NY 11788.
    ANDA 080521Isoniazid Tablets, 300 mgWatson Laboratories, Inc.
    ANDA 086537Nitroglycerin Controlled-Release Capsules, 6.5 mgLumara Health, Inc., 1100 Winter St., Suite 3000, Waltham, MA 02451.
    ANDA 086889Disulfiram Tablets, 250 mgWatson Laboratories, Inc.
    ANDA 086890Disulfiram Tablets, 500 mgWatson Laboratories, Inc.
    ANDA 087975Nitroglycerin Controlled-Release Capsules, 2.5 mgSandoz Inc., 100 College Rd. West, Princeton, NJ 08540.
    ANDA 087976Nitroglycerin Controlled-Release Capsules, 6.5 mgDo.
    ANDA 088509Nitroglycerin Controlled-Release Capsules, 9 mgDo.
    ANDA 090833Carbidopa/Levodopa and Entacapone Tablets, 18.75 mg/200 mg/75 mg, 25 mg/200 mg/100 mg, 31.25 mg/200 mg/125 mg, 37.5 mg/200 mg/150 mg, and 50 mg/200 mg/200 mgMorton Grove Pharmaceuticals Inc./Wockhardt USA LLC., 6451 Main St., Morton Grove, IL 60053.
    ANDA 200771Irinotecan HCl Injection, 40 mg/2 mL (20 mg/mL) and 100 mg/5 mL (20 mg/mL)Heritage Pharmaceuticals Inc. d/b/a/Avet Pharmaceuticals Inc. U.S. Agent for Emcure Pharmaceuticals Limited, One Tower Center Blvd., East Brunswick, NJ 08816.
    ANDA 202063Gemcitabine HCl for Injection, EQ 200 mg base/vial; EQ 1 gram base/vialDo.
    ANDA 204437Sodium Fluoride 18 Injection, 10-200 millicurie (mCi)/mLUCSF Radiopharmaceutical Facility, 185 Berry St., Suite 350, San Francisco, CA 94107.
    ANDA 208444Choline C-11 Injection, 4-33.1 mCi/mLDo.

    Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of July 26, 2021. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on July 26, 2021 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

    Start Signature

    Dated: June 21, 2021.

    Lauren K. Roth,

    Acting Principal Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2021-13593 Filed 6-24-21; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
06/25/2021
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2021-13593
Dates:
Approval is withdrawn as of July 26, 2021.
Pages:
33718-33719 (2 pages)
Docket Numbers:
Docket No. FDA-2021-N-0492
PDF File:
2021-13593.pdf
Supporting Documents:
» Watson Laboratories, Inc., et al.; Withdrawal of Approval of 36 Abbreviated New Drug Applications; Correction
» Watson Laboratories, Inc. et al.; Withdrawal of Approval of 36 Abbreviated New Drug Applications